Tevogen Bio Holdings (TVGN) Depreciation & Amortization (CF) (2023 - 2026)
Tevogen Bio Holdings (TVGN) reported Depreciation & Amortization (CF) of $30268.0 for Q1 2026, down 25.36% on a YoY basis from $40553.0 in Q1 2025, and down 47.87% quarter-over-quarter from $58061.0 in Q4 2025.
Tevogen Bio Holdings (TVGN) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $30268.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 25.36% year-over-year to $30268.0; the trailing twelve-month figure through Mar 2026 stood at $180288.0 (up 11.14% YoY), and the FY2025 full-year result was $190573.0, up 17.49% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $30268.0, down from $58061.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $91441.0 in Q2 2025, with the low at $518.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $42026.9 across 4 years, with a median of $40552.0 in 2024.
- The largest YoY upside for Depreciation & Amortization (CF) was 125.49% in 2025 against a maximum downside of 98.72% in 2025.
- Tevogen Bio Holdings' Depreciation & Amortization (CF) stood at $44094.0 in 2023, then decreased by 8.03% to $40552.0 in 2024, then soared by 43.18% to $58061.0 in 2025, then plunged by 47.87% to $30268.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $30268.0 (Q1 2026), $58061.0 (Q4 2025), and $518.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1,395.22 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 429,663.65 |
| 10 | Tevogen Bio Holdings | 182.04 Mn | 181.35 Mn | - | 30,268.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,268.00 |
| Mar 31, 2026 | 30,268.00 |
| Dec 31, 2025 | 58,061.00 |
| Dec 31, 2025 | 58,061.00 |
| Sep 30, 2025 | 518.00 |
| Sep 30, 2025 | 518.00 |
| Jun 30, 2025 | 91,441.00 |
| Jun 30, 2025 | 91,441.00 |
| Mar 31, 2025 | 40,553.00 |
| Mar 31, 2025 | 40,553.00 |
| Dec 31, 2024 | 40,552.00 |
| Dec 31, 2024 | 40,552.00 |
| Sep 30, 2024 | 40,553.00 |
| Sep 30, 2024 | 40,553.00 |
| Jun 30, 2024 | 40,552.00 |
| Jun 30, 2024 | 40,552.00 |
| Mar 31, 2024 | 40,552.00 |
| Mar 31, 2024 | 40,552.00 |
| Dec 31, 2023 | 44,094.00 |
| Dec 31, 2023 | 44,094.00 |